4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:血管内皮生长因子-C, Spp1, IRF-3, DPYSL2, GLUT5
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Sandwich_method_ELISA > IBL/Interleukin-4 (IL-4) ELISA/BE53041/
商品详细IBL/Interleukin-4 (IL-4) ELISA/BE53041/
IBL/Interleukin-4 (IL-4) ELISA/BE53041/
IBL/Interleukin-4 (IL-4) ELISA/BE53041/
商品编号: BE53041
品牌: TECAN
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 夹心法ELISA
公司分类: Sandwich_method_ELISA
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
Kitsize12x8
MethodELISA
Incubationtime1x2h,1x1h,1x10min
Standardrange7.8-500pg/mL
Specimen/Volumes50µLserum,plasma,urine,cellculturesupernatant
Substrate/isotopeTMB450nm
RegulatoryStatus:EU:CE
Detailsfor: Interleukin-4(IL-4)ELISA
HumanIL-4existinmolecularweightformsbetween15and19kDa,representingvariableglycosylation.ThegeneforhumanIL-4isfoundonthelongarmofchromsome5incloseassociationwithgenesforIL-13,IL-5GM-CSFandIL-3.IL-4mediatesitsfunctionbybindingtoreceptorsexpressedontargetcells.ReceptorsexistonfreshlypreparedBandTlymphocytesandmacrophages,aswellasonvariouscelllinesincludinglymphoidcells,mastcelllines,avarietyofotherhematopoieticcelllines,fibroblastsandstromalcelllines.OnTandBcells,receptorsarepresentinlownumbers(appr.400),whicharereportedtobeup-regulatedbyIL-2andIL-4.IL-4isproducedbyaparticularsubsetofThelpercells,theTH2cells.ThesecellstendtomakeaspecificsetoflymphokinesincludingIL-4,IL-5,IL-6,IL-10,IL-13,IL-3andGM-CSFandfailtoproduceIL-2,IFNgamma,andlymphotoxin(TNFbeta).ApartfromTcells,ithasbeenshownthatmastcellscanproduceIL-4.IL-4exertsnumerouseffectsonvarioushematopoieticcelltypes.OnBcells,IL-4promotesimmunologicalclassswitchingtoIgEandIgG1isotypesandupregulatesMHCclassIIandCD23expression.Itcanpromotesurvival,growth,anddifferentiationofbothTandBlymphocytes,mastcells,andendothelialcells.Inaddition,IL-4caninhibittheproductionofTNF,IL-1,andIL-6bymacrophages.
ForconcretedatapleaseconsulttheInstructionforUseinthedownloadboxontherightside.
品牌介绍
IBL我们的愿景是通过Tecan技术,产品和支持,为世界各地的每个实验室提供支持。我们旨在通过无与伦比的专业知识,产品和客户支持来塑造生命科学和临床诊断自动化工作流程的未来。